Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH).

Full DD Report for AMPH

You must become a subscriber to view this report.


Recent News from (NASDAQ: AMPH)

FDA OKs first non-opioid treatment for opioid withdrawal
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 16 2018 16:44
Amphastar Pharmaceuticals' (AMPH) Q1 2018 Results - Earnings Call Transcript
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2018 Earnings Conference Call May 09, 2018 05:00 PM ET Executives Jason Shandell - President Bill Peters - CFO Analysts David Amsellem - Piper Jaffray David Maris - Wells Fargo Gary Nachman - BMO Capital Markets David Steinberg ...
Source: SeekingAlpha
Date: May, 14 2018 14:20
Amphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection
RANCHO CUCAMONGA, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Calcium Ch...
Source: GlobeNewswire
Date: May, 14 2018 06:00
Amphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
RANCHO CUCAMONGA, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO, will be presenting at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018 at 1:00 p.m....
Source: GlobeNewswire
Date: May, 10 2018 06:00
Amphastar misses by $0.13, misses on revenue
Amphastar (NASDAQ: AMPH ): Q1 EPS of -$0.05 misses by $0.13 . More news on: Amphastar, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 09 2018 16:22
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
Reports Net Revenues of $58.4 Million for the Three Months Ended March 31, 2018 RANCHO CUCAMONGA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”) today reported results for the three months...
Source: GlobeNewswire
Date: May, 09 2018 16:05
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2018
RANCHO CUCAMONGA, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2018 ended March 31, 2018, after the market closes on Wednesday, May 9, 2018, and will hold a conference call to ...
Source: GlobeNewswire
Date: May, 03 2018 16:05
Opioid prescriptions dropped 12% in 2017
Opioid prescriptions dropped 12% in 2017, according to a report from the IQVIA Institute for Human Data Science. More news on: Johnson & Johnson, Endo International plc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: April, 26 2018 03:18
U.S. opioid prescriptions down 12% last year, largest drop in 25 years
According to IQVIA ( IQV -0.8% ), U.S. opioid prescriptions declined 12% in 2017, the largest annual drop in 25 years as doctors respond to the opioid crisis. More news on: IQVIA Holdings, Inc., Insys Therapeutics, Inc., Johnson & Johnson, Healthcare stocks news, News on ETFs, ...
Source: SeekingAlpha
Date: April, 19 2018 11:25
DEA aiming to collar production of opioids
The U.S. Drug Enforcement Administration (DEA) has unveiled plans to restrict the amount of opioids made by drug firms if it believes the medications are being diverted for illicit use. The proposed new rules were announced today in a speech by Attorney General Jeff Sessions. More news o...
Source: SeekingAlpha
Date: April, 17 2018 15:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1715.9116.2216.3315.91205,313
2017-06-2016.8817.1417.7516.80440,805
2017-06-1916.7516.9317.0016.545360,679
2017-06-1616.5016.6216.9216.32973,528
2017-06-1516.0716.1816.3315.84275,861

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-178,04311,15472.1087Short
2018-08-1629,70944,81566.2925Short
2018-08-1518,04525,07171.9756Short
2018-08-149,86824,88839.6496Short
2018-08-1316,45530,72653.5540Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AMPH.


About Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)

Logo for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $747,171,591 - 05/14/2018
  • Issue and Outstanding: 46,350,595 - 03/06/2018

 


Recent Filings from (NASDAQ: AMPH)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 18 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 18 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 14 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 09 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 19 2018

 

 


Daily Technical Chart for (NASDAQ: AMPH)

Daily Technical Chart for (NASDAQ: AMPH)


Stay tuned for daily updates and more on (NASDAQ: AMPH)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AMPH)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AMPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AMPH and does not buy, sell, or trade any shares of AMPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/